Crispr Therapeutics AG (NASDAQ:CRSP) Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

NASDAQ CRSP opened at $71.65 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics AG has a fifty-two week low of $22.22 and a fifty-two week high of $74.00. The stock has a market cap of $3.80 billion, a PE ratio of -20.83 and a beta of 3.15. The firm’s fifty day moving average price is $49.98 and its two-hundred day moving average price is $46.23.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the consensus estimate of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. As a group, sell-side analysts predict that Crispr Therapeutics AG will post 0.65 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Benjamin Edwards Inc. boosted its position in Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after acquiring an additional 268 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Crispr Therapeutics by 13.6% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock valued at $118,000 after acquiring an additional 343 shares during the last quarter. Traynor Capital Management Inc. raised its holdings in shares of Crispr Therapeutics by 5.8% during the third quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock valued at $280,000 after purchasing an additional 375 shares during the period. Commonwealth Equity Services LLC raised its holdings in shares of Crispr Therapeutics by 2.2% during the third quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock valued at $746,000 after purchasing an additional 386 shares during the period. Finally, D. E. Shaw & Co. Inc. raised its holdings in shares of Crispr Therapeutics by 7.1% during the second quarter. D. E. Shaw & Co. Inc. now owns 7,019 shares of the company’s stock valued at $331,000 after purchasing an additional 467 shares during the period. 49.81% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have recently issued reports on CRSP. BidaskClub upgraded Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday. Oppenheimer lifted their price target on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research report on Monday, November 25th. Chardan Capital reiterated a “buy” rating and issued a $72.50 price target on shares of Crispr Therapeutics in a research report on Monday, November 18th. Piper Jaffray Companies reiterated a “buy” rating and issued a $104.00 price target on shares of Crispr Therapeutics in a research report on Tuesday, November 26th. Finally, Zacks Investment Research downgraded shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Two analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $69.54.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: What member countries make up the G-20?

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link